CVM
CEL-SCI Corporation
NYSE American Healthcare United States
1,52 $US
-1.94% today
-70.49% YTD · -83.50% 1Y
4
Insider transactions
SEC Form 4 · AMF · BaFin — rolling 90 days
5
Hedge funds tracked
Latest available SEC 13F filings
55
/ 100
MIXED

Analysis CEL-SCI Corporation (CVM) — Kairos Score 55/100

Composite score aggregating 8 smart money dimensions: insiders (SEC/AMF/BaFin), hedge funds, politicians & gurus, price momentum, valuation, analyst consensus, financial health, earnings momentum. The higher the score, the more favorable the institutional signals consensus.

💡 Detailed breakdown (the 8 sub-scores) available in the Premium dashboard.

About CEL-SCI Corporation

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development to treat cancer and other diseases by using the immune system in the United States. The company's lead immunotherapy is Multikine, which has completed Phase III clinical trials for the potential treatment of certain head and neck cancers. It is also developing Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer, as well as to potentially treat rheumatoid arthritis. In addition, the company's LEAP product candidates include CEL-2000; CEL-4000; and CEL-5000 that are in preclinical trials for potential rheumatoid arthritis therapeutic treatments. CEL-SCI Corporation has a strategic partnership with Saudi Arabian Pharma Company for Multikine in the treatment of head and neck cancer. The company was incorporated in 1983 and is headquartered in Vienna, Virginia.

Key info

👔
CEO
Mr. Geert R. Kersten Esq.
📍
HQ
8229 Boone Boulevard, Suite 802, Vienna, VA, 22182, United States
💰
Market cap
26 735 262,00 $US
💸
Dividend yield
0.00%

🕴️ Insider activity (90 days)

4 transactions — 1 buys and 0 sales reported by CEL-SCI Corporation executives.

TE
TALOR EYAL
Chief Scientific Officer · 2026-09-30
Other
PP
PRICHEP PATRICIA B
Chief Financial Officer · 2026-09-30
Other
KG
KERSTEN GEERT R
Chief Executive Officer · 2026-09-30
Other

🏦 Hedge Funds

5 institutional funds report a position on CVM in their latest SEC quarterly filing.

VANGUARD GROUP INC
RENAISSANCE TECHNOLOGIES LLC
VANGUARD CAPITAL MANAGEMENT LLC
CITADEL ADVISORS LLC
MAI Capital Management

📰 Recent news

11 recent articles on CVM.

🧠 What makes Kairos Insider

Beyond raw data, we aggregate and score every smart money signal to give you a unique view.

🧠

Kairos Score 0-100

8-dimension composite score: insiders · hedge funds · politicians · momentum · valuation · health · analysts · earnings.

🎯

Insider Clusters

Detection of clustered purchases or sales by several executives in the same stock.

🏦

13F Hedge Funds

Berkshire, Pershing Square, Tiger Global, Bridgewater and other reporting funds.

📈

ETF Rotations

NANC & GOP (Pelosi & Republicans), GURU (top hedge funds), ARK (Cathie Wood). See who enters and exits each week.

🔥

Google Trends

Spot marked changes in search interest around the stocks being followed.

📧

Email alerts

Create your watchlist and receive a brief of events affecting your tickers.

Companies in the same sector as CEL-SCI Corporation

Official sources · Public data · SEC EDGAR — Form 4 & 13F · AMF — Executive filings · BaFin — Directors' Dealings · Yahoo Finance · Alpha Vantage

🔓 Unlock the full analysis

This public page only shows a preview. The full analysis of CVM on the Kairos Insider dashboard includes:

✅ Full Kairos Score (8-axis radar + synthesis)
✅ History of all 4 insider transactions over 90 days
✅ All 5 detected institutional funds
✅ Thematic ETFs (ARK, BUZZ, NANC, GOP, JEPI…)
✅ Hot Stocks Google Trends
✅ Available history: AUM + rotations
✅ Fundamentals (P/E, PEG, EV/EBITDA, ROE…)
✅ Financial health (Altman Z, Piotroski F)
✅ Sector peers + recent earnings
See full analysis →
Analyze other tickers for free →

Free signup · Pro €19/month or €190/year